ALAMEDA, Calif.— InSite Vision Incorporated (OTCBB: INSV) reported financial results for the quarter ended Sept. 30, 2014. Revenues for the third quarter of 2014 were $0.4 million compared to $5.3 million for the same period in 2013.

In the third quarter of 2013, revenues included an additional $3.7 minimum royalty true-up payment for net sales of AzaSite. Net loss for the third quarter of 2014 was $3.3 million, compared to net income of $0.6 million in the third quarter of 2013.

“The third quarter was marked by continued regulatory progress for BromSite and for DexaSite. We have maintained our focus on filing two NDAs with the U.S. Food and Drug Administration for marketing approval of these products, and establishing the regulatory pathways toward the approval of both products in Europe,” said Timothy Ruane, InSite’s CEO.